Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Dyne Therapeutics (DYN)
NASDAQ:DYN
Dyne Therapeutics (DYN) Stock Price & Analysis
215 Followers
DYN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$6.40 - $30.27
Previous Close$25.65
Volume464.28K
Average Volume (3M)1.27M
Market Cap
$2.08B
Enterprise Value$1.98B
Total Cash (Recent Filing)$123.10M
Total Debt (Recent Filing)$27.41M
Price to Earnings (P/E)-6.5
Beta1.07
Next Earnings
Aug 01, 2024EPS Estimate
-$0.75Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.96
Shares Outstanding87,382,638
10 Day Avg. Volume762,117
30 Day Avg. Volume1,270,707
Standard Deviation0.23
R-Squared0.05
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)25.13
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-16.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-8.38
Forecast
1Y Price Target
$37.29Price Target Upside45.15% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
Dyne Therapeutics News
PremiumCompany Announcements
Dyne Therapeutics Welcomes John Cox as New CEO and Board Member
PremiumPress Releases
Dyne Therapeutics Announces CEO TransitionBulls Say, Bears Say
Bulls Say
Clinical Trial ResultsDyne reported positive first in human data for its lead assets, DYNE-101 and DYNE-251, showing promise with safety and potential efficacy.
Regulatory MilestonesDYNE-101 and DYNE-251 achieved significant regulatory designations, enhancing their potential for expedited development paths.
Technology PlatformDyne's innovative FORCE platform is poised to revolutionize treatment delivery to muscle tissues, underscoring a unique competitive edge.
Bears Say
Clinical Trial ResultsThe data from only 12 patients without the placebo comparison might not be sufficient to predict the effectiveness of AOC 1001.
Financial HealthThe company's cash reserves, along with equivalents and marketable securities, have decreased significantly since the end of the last fiscal year.
Operational CostsThe company's cash burn from operations indicates a substantial rate of spending, which could impact its financial stability.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
DYN FAQ
What was Dyne Therapeutics’s price range in the past 12 months?
Dyne Therapeutics lowest stock price was $6.40 and its highest was $30.27 in the past 12 months.
What is Dyne Therapeutics’s market cap?
Currently, no data Available
When is Dyne Therapeutics’s upcoming earnings report date?
Dyne Therapeutics’s upcoming earnings report date is Aug 01, 2024 which is in 82 days.
How were Dyne Therapeutics’s earnings last quarter?
Dyne Therapeutics released its earnings results on May 02, 2024. The company reported -$0.81 earnings per share for the quarter, missing the consensus estimate of -$0.8 by -$0.01.
Is Dyne Therapeutics overvalued?
According to Wall Street analysts Dyne Therapeutics’s price is currently Undervalued.
Does Dyne Therapeutics pay dividends?
Dyne Therapeutics does not currently pay dividends.
What is Dyne Therapeutics’s EPS estimate?
Dyne Therapeutics’s EPS estimate is -$0.75.
How many shares outstanding does Dyne Therapeutics have?
Dyne Therapeutics has 81,106,150 shares outstanding.
What happened to Dyne Therapeutics’s price movement after its last earnings report?
Dyne Therapeutics reported an EPS of -$0.81 in its last earnings report, missing expectations of -$0.8. Following the earnings report the stock price went up 0.308%.
Which hedge fund is a major shareholder of Dyne Therapeutics?
Among the largest hedge funds holding Dyne Therapeutics’s share is Woodline Partners LP. It holds Dyne Therapeutics’s shares valued at 6M.
---
Dyne Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.29 (45.15% Upside)
$37.29 (45.15% Upside)
Blogger Sentiment
Bullish
DYN Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 99.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $16.7M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.9%
Last 30 Days ▼ 6.4%
Last 30 Days ▼ 6.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
83.60%
12-Months-Change
Fundamentals
Return on Equity
-71.50%
Trailing 12-Months
Asset Growth
80.94%
Trailing 12-Months
Company Description
Dyne Therapeutics
Dyne Therapeutics Inc is a bio-technology company focused on providing therapeutics for patients with genetically driven diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
---
DYN Stock 12 Month Forecast
Average Price Target
$37.29
▲(45.15% Upside)
Technical Analysis
Best Analysts Covering DYN
1 Year
1 Year Success Rate
7/10 ratings generated profit
1 Year Average Return
+60.54%
reiterated a buy rating 6 days ago
Copying Keay Nakae's trades and holding each position for 1 Year would result in 70.00% of your transactions generating a profit, with an average return of +60.54% per trade.
---